10-Jul-2026
Senseonics and Welldoc Partner to Develop Next-Generation App for Eversense 365
Globe Newswire (Wed, 10-Jun 8:00 AM ET)
Globe Newswire (Sat, 6-Jun 5:00 PM ET)
Globe Newswire (Mon, 1-Jun 8:00 AM ET)
SENS Revenue Surges 87% Year-Over-Year as Eversense 365 Launch Drives Commercial Momentum
Market Chameleon (Fri, 8-May 7:27 AM ET)
Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 4:01 PM ET)
Senseonics Closes $92 Million Offering: What This Means for Future Growth and Investor Confidence
Market Chameleon (Tue, 5-May 5:49 AM ET)
Globe Newswire (Mon, 4-May 4:01 PM ET)
Globe Newswire (Mon, 4-May 8:00 AM ET)
Globe Newswire (Fri, 1-May 9:10 AM ET)
Market Chameleon (Fri, 1-May 3:06 AM ET)
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
Senseonics Holdings trades on the NASDAQ stock market under the symbol SENS.
As of July 10, 2026, SENS stock price climbed to $5.38 with 356,706 million shares trading.
SENS has a beta of 1.89, meaning it tends to be more sensitive to market movements. SENS has a correlation of 0.10 to the broad based SPY ETF.
SENS has a market cap of $280.85 million. This is considered a Small Cap stock.
Last quarter Senseonics Holdings reported $12 million in Revenue and -$.71 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.02.
In the last 3 years, SENS traded as high as $28.00 and as low as $4.79.
The top ETF exchange traded funds that SENS belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
SENS has underperformed the market in the last year with a price return of -46.2% while the SPY ETF gained +21.8%. SENS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.5% and -5.9%, respectively, while the SPY returned +11.4% and +3.6%, respectively.
SENS support price is $5.11 and resistance is $5.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SENS shares will trade within this expected range on the day.
